相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Management of Acute Hepatitis C
Anurag Maheshwari et al.
Clinics in Liver Disease (2010)
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
Mark G. Swain et al.
GASTROENTEROLOGY (2010)
Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus-Induced Cirrhosis. A 12-Year Prospective Follow-up Study
Savino Bruno et al.
HEPATOLOGY (2010)
The quasispecies nature and biological implications of the hepatitis C virus
Sarah L. Fishman et al.
INFECTION GENETICS AND EVOLUTION (2009)
HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON (TM) (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C
P. Kwo et al.
JOURNAL OF HEPATOLOGY (2009)
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
Alexander Ploss et al.
NATURE (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
Sarah Maylin et al.
GASTROENTEROLOGY (2008)
Hepatitis C genotype 4: What we know and what we don't yet know
Sanaa M. Kamal et al.
HEPATOLOGY (2008)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
Bart J. Veldt et al.
ANNALS OF INTERNAL MEDICINE (2007)
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha
Mitchell L. Shiffman et al.
HEPATOLOGY (2007)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Mitchell L. Shiffman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epidemiology of hepatitis C virus infection
Miriam J. Alter
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
Matthew J. Evans et al.
NATURE (2007)
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
Savino Bruno et al.
HEPATOLOGY (2007)
Impact of reducing peginterferon alfa-2a and ribavirin dose during Retreatment in patients with chronic hepatitis C
Mitchell L. Shiffman et al.
GASTROENTEROLOGY (2007)
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
Eric Snoeck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
Joseph F. Perz et al.
JOURNAL OF HEPATOLOGY (2006)
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin
Jean-Pierre Bronowicki et al.
GASTROENTEROLOGY (2006)
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment
Jose M. Sanchez-Tapias et al.
GASTROENTEROLOGY (2006)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
DM Jensen et al.
HEPATOLOGY (2006)
Diverse effects of cyclosporine on hepatitis C virus strain replication
N Ishii et al.
JOURNAL OF VIROLOGY (2006)
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting
CP Desmond et al.
JOURNAL OF VIRAL HEPATITIS (2006)
Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection
YM Loo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
T Berg et al.
GASTROENTEROLOGY (2006)
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy
E Formann et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
The interferon response circuit: Induction and suppression by pathogenic viruses
O Haller et al.
VIROLOGY (2006)
Mechanistic link between the anti.HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade
Y Huang et al.
HEPATOLOGY (2006)
Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes
S Griffin et al.
JOURNAL OF VIROLOGY (2005)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies
F Fabrizi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci et al.
JOURNAL OF HEPATOLOGY (2005)
Adaptive immune responses in acute and chronic hepatitis C virus infection
DG Bowen et al.
NATURE (2005)
Evasion of intracellular host defence by hepatitis C virus
M Gale et al.
NATURE (2005)
Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors
BK Biswal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication
AM Domitrovich et al.
VIROLOGY (2005)
Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKε
A Breiman et al.
JOURNAL OF VIROLOGY (2005)
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
M Romero-Gómez et al.
GASTROENTEROLOGY (2005)
Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis
Y Kamegaya et al.
HEPATOLOGY (2005)
Mutational analysis of hepatitis C virus nonstructural protein 5A: Potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain
N Appel et al.
JOURNAL OF VIROLOGY (2005)
Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome
N Franck et al.
JOURNAL OF VIROLOGY (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China
RJ Garten et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2004)
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
MF Abdelmalek et al.
LIVER TRANSPLANTATION (2004)
Toll-like receptor control of the adaptive immune responses
A Iwasaki et al.
NATURE IMMUNOLOGY (2004)
Hepatitis C virus NS5A: tales of a promiscuous protein
A Macdonald et al.
JOURNAL OF GENERAL VIROLOGY (2004)
Induction and regulation of IFNs during viral infections
L Malmgaard
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2004)
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
F Carrat et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA
H Ji et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
RT Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
FJ Torriani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of the hepatitis C virus core protein on innate cellular defense pathways
K Miller et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2004)
The NS5A protein of hepatitis C virus is a zinc metalloprotein
TL Tellinghuisen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities
EA Prikhod'ko et al.
VIROLOGY (2004)
CD81 is an entry coreceptor for hepatitis C virus
EG Cormier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
B Bartosch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Hepatitis C and renal disease: An update
CM Meyers et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences
A Sakai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
GL Davis et al.
HEPATOLOGY (2003)
Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-γ stimuli
A Hosui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: A prospective study of 12,008 men in Taiwan
CA Sun et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2003)
Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses
M Qiao et al.
HEPATOLOGY (2003)
Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection
F Masciopinto et al.
VIROLOGY (2002)
Adherence to combination therapy enhances sustained response in genotyp-1-infected patients with chronic hepatitis C
JG McHutchison et al.
GASTROENTEROLOGY (2002)
Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption
R Germi et al.
JOURNAL OF MEDICAL VIROLOGY (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Characteristics of hepatitis C in renal transplant candidates
SJ Cotler et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2002)
Hepatitis C virus and its roles in cell proliferation
K Shimotohno et al.
JOURNAL OF GASTROENTEROLOGY (2002)
Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group
KE Sherman et al.
CLINICAL INFECTIOUS DISEASES (2002)
An amino-terminal amphipathic α-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A
V Brass et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future
H Yoshizawa
ONCOLOGY (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
KL Lindsay et al.
HEPATOLOGY (2001)
Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice
M Lechmann et al.
HEPATOLOGY (2001)
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection
I Bica et al.
CLINICAL INFECTIOUS DISEASES (2001)
Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C
KR Reddy et al.
HEPATOLOGY (2001)
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study
G Greub et al.
LANCET (2000)
Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer
N Kato et al.
HEPATOLOGY (2000)
Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection
A Meola et al.
JOURNAL OF VIROLOGY (2000)
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death
F Degos et al.
GUT (2000)
De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus
GX Luo et al.
JOURNAL OF VIROLOGY (2000)
Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
Y Allory et al.
HUMAN PATHOLOGY (2000)
分享论文
